Track outcomes in adults with moderate-to-severe psoriasis
Part of Skin clinical trials.
This study keeps track of how people with moderate-to-severe psoriasis do over time while using Siliq or other approved treatments. It may help researchers understand how treatments compare in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with moderate-to-severe psoriasis by a dermatologist
- You are at least 18 years old
- You started or switched a whole-body (systemic) psoriasis treatment within the last 12 months
- You can and are willing to give informed consent to join the registry
- You are not currently in, and do not plan to join, a drug study testing an experimental (investigational) treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
This study follows patients with moderate to severe psoriasis who are starting a new advanced medication for the first time. Researchers will track how well the treatment works early on to understand what helps different patients improve.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.